There are 2789 resources available
342O - Intracranial administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in recurrent glioblastoma (rGB): A multi-cohort adaptive phase I clinical trial
Presenter: Bart Neyns
Session: Proffered Paper session - CNS tumours
Resources:
Abstract
Slides
Webcast
LBA56 - Perioperative or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Results of the NEONAX trial, a randomized phase II AIO study
Presenter: Thomas Seufferlein
Session: Proffered Paper session - Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast
LBA57 - Unicancer PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC)
Presenter: Thierry Conroy
Session: Proffered Paper session - Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast
Yes, ready for primetime in the clinic
Presenter: Paolo Ascierto
Session: Stay at the bench or move to the bedside: What is the role for neoadjuvant therapy in melanoma today?
Resources:
Slides
Webcast
No, appropriate for clinical trial/biomarker work at this time
Presenter: Reinhard Dummer
Session: Stay at the bench or move to the bedside: What is the role for neoadjuvant therapy in melanoma today?
Resources:
Slides
Webcast
Polling 2 (led by chair)
Presenter: Omid Hamid
Session: Stay at the bench or move to the bedside: What is the role for neoadjuvant therapy in melanoma today?
Resources:
Slides
Webcast
Q&A
Presenter: Omid Hamid
Session: Stay at the bench or move to the bedside: What is the role for neoadjuvant therapy in melanoma today?
Resources:
Slides
Webcast
Introduction by the chair
Presenter: Omid Hamid
Session: Stay at the bench or move to the bedside: What is the role for neoadjuvant therapy in melanoma today?
Resources:
Slides
Webcast
LBA4_PR - Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol
Presenter: Gerhardt Attard
Session: Presidential symposium 2
Resources:
Abstract
Slides
Webcast
LBA5_PR - A phase III trial with a 2x2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: Overall survival with abiraterone acetate plus prednisone in PEACE-1
Presenter: Karim Fizazi
Session: Presidential symposium 2
Resources:
Abstract
Slides
Webcast